Literature DB >> 27604316

Clinical and laboratory tests for the diagnosis of heparin-induced thrombocytopenia.

Michael Nagler, Tamam Bakchoul1.   

Abstract

A rapid diagnostic work-up is required in patients with suspected heparin-induced thrombocytopenia (HIT). However, diagnosis of HIT is challenging due to a number of practical issues and methodological limitations. Many laboratory tests and a few clinical scoring systems are available but the individual characteristics and the diagnostic accuracy of these are hard to appraise. The 4Ts score is a well evaluated clinical assessment tool with the potential to rule out HIT in many patients. Still, it requires experience and is subject to a relevant inter-observer variability. Immunoassays such as enzyme-linked immunosorbent assays or recently developed rapid assays are able to exclude HIT in a number of patients. But, accuracy of immunoassays differs depending on type of assay, threshold, antibody specificity and even manufacturer. Due to a comparatively low positive predictive value, HIT cannot be confirmed by immunoassays alone. In addition, only some of them are immediately accessible, particularly in small laboratories. While functional assays such as the serotonin release assay (SRA) and the heparin-induced platelet activation assay (HIPA) are considered as gold standard for diagnosis of HIT, they require a highly specialised laboratory. In addition, some of them are not adequately evaluated. In clinical practice, we recommend an integrated diagnostic approach combining not only clinical assessment (the 4Ts score) but immunoassays and functional assays as well. We propose a clear diagnostic algorithm supporting clinical decision-making. Furthermore, we provide an overview of all current laboratory techniques for HIT and discuss diagnostic pathways and strategies to reduce diagnostic errors, and future perspectives.

Entities:  

Keywords:  Heparin/adverse effects; immunoassay/methods; thrombocytopenia/chemically induced; thrombocytopenia/diagnosis

Mesh:

Substances:

Year:  2016        PMID: 27604316     DOI: 10.1160/TH16-03-0240

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  7 in total

Review 1.  Drug-associated thrombocytopenia.

Authors:  Tamam Bakchoul; Irene Marini
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2018-11-30

2.  Heparin-induced thrombocytopenia: ELISA optical density value and 4T score in correlation with panel donor platelets activation in functional flow cytometric assay.

Authors:  Klara Železnik; Primož Rožman; Eva Kocjan; Elvira Maličev
Journal:  Blood Transfus       Date:  2020-10-09       Impact factor: 3.443

3.  Rapid immunoassays for diagnosis of heparin-induced thrombocytopenia: Comparison of diagnostic accuracy, reproducibility, and costs in clinical practice.

Authors:  Andriyana Bankova; Yvonne Andres; Michael P Horn; Lorenzo Alberio; Michael Nagler
Journal:  PLoS One       Date:  2017-06-08       Impact factor: 3.240

4.  Combination of two complementary automated rapid assays for diagnosis of heparin-induced thrombocytopenia (HIT).

Authors:  Theodore E Warkentin; Jo-Ann I Sheppard; James W Smith; Na Li; Jane C Moore; Donald M Arnold; Ishac Nazy
Journal:  J Thromb Haemost       Date:  2020-04-27       Impact factor: 5.824

Review 5.  Functional Assays in the Diagnosis of Heparin-Induced Thrombocytopenia: A Review.

Authors:  Valentine Minet; Jean-Michel Dogné; François Mullier
Journal:  Molecules       Date:  2017-04-11       Impact factor: 4.411

6.  Suspected heparin-induced thrombocytopenia in a COVID-19 patient on extracorporeal membrane oxygenation support: a case report.

Authors:  Xuan T Phan; Tuan H Nguyen; Tung T Tran; Thu-Hien T Huynh; Thuy-Ha T Hoang; Vinh-Chau V Nguyen; Thao N T Pham
Journal:  Thromb J       Date:  2020-12-14

7.  Heparin-Induced Thrombocytopenia in Iranian Cardiac Surgery Patients Using the 4Ts Clinical Scoring System and Laboratory Methods.

Authors:  Minoo Ahmadinejad; Massoumeh Shahbazi; Azita Chegini
Journal:  Int J Hematol Oncol Stem Cell Res       Date:  2021-10-01
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.